Table 2.
Evolution of [18F]DOPA uptake and [11C]Raclopride, [11C]DASB, and [18F]MPPF bindings among the different states and the different regions of interest
| Region | Part | [18F]Dopa Ki unit × 10−3 min−1 |
[11C]Raclopride BPND |
[11C]DASB BPND |
[18F]MPPF BPND |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n = 7) | Early (n = 4) | Symptomatic (n = 7) | Recovered (n = 7) | Baseline (n = 5) | Early (n = 4) | Symptomatic (n = 6) | Recovered (n = 7) | Baseline (n = 5) | Symptomatic (n = 5) | Recovered (n = 4) | Baseline (n = 7) | Early (n = 4) | Symptomatic (n = 7) | Recovered (n = 7) | ||
| Putamen | Anterior | 5 ± 2.2 | 5.3 ± 2.2 | 2.2 ± 2† | 2 ± 0.8‡ | 3.7 ± 0.8 | 3.8 ± 0.4 | 4.2 ± 0.6 | 3.3 ± 0.7†‡ | 1.17 ± 0.2 | 1.3 ± 0.3 | 1.19 ± 0.2 | 0.74 ± 0.2 | 0.89 ± 0.2 | 0.84 ± 0.2 | 0.79 ± 0.1 |
| Posterior | 5.2 ± 2.3 | 6.2 ± 3.6 | 1.9 ± 2.3†/*† | 1.3 ± 0.7‡/*‡ | 4 ± 0.3 | 4.6 ± 0.2 | 4.9 ± 0.4 | 4.1 ± 0.8 | 1.09 ± 0.2 | 1.24 ± 0.2† | 1.13 ± 0.2†‡0.058 | 0.62 ± 0.2 | 0.72 ± 0.2 | 0.7 ± 0.1 | 0.65 ± 0.2 | |
| Caudate | Anterior | 4.3 ± 2.3 | 3.8 ± 1.9 | 1.8 ± 1.7† | 1.9 ± 0.8‡0.053 | 3.6 ± 0.5 | 3.7 ± 0.3 | 4 ± 0.5†0.06 | 3 ± 1.1†‡ | 0.88 ± 0.2 | 1.02 ± 0.3 | 0.92 ± 0.2 | 0.56 ± 0.2 | 0.73 ± 0.2*0.06 | 0.66 ± 0.2 | 0.67 ± 0.1 |
| Posterior | 3.8 ± 2.2 | 3.8 ± 2.8 | 1 ± 1.1†/*† | 1.1 ± 0.6‡/*‡ | 3.1 ± 0.2 | 3.5 ± 0.5 | 3.6 ± 0.7 | 2.8 ± 1.1 | 0.9 ± 0.2 | 1.04 ± 0.3 | 0.94 ± 0.2 | 0.38 ± 0.1 | 0.44 ± 0.1 | 0.42 ± 0.1 | 0.45 ± 0.2 | |
| Ventral striatum | Anterior | 3.4 ± 1.6 | 4.1 ± 1.4 | 2.8 ± 1.5 | 3.2 ± 0.7 | 2 ± 0.6 | 2 ± 0.4 | 2 ± 0.4 | 1.8 ± 0.3 | 1.11 ± 0.3 | 1.18 ± 0.5 | 1.15 ± 0.3 | 0.64 ± 0.2 | 0.81 ± 0.3 | 0.72 ± 0.2 | 0.69 ± 0.2 |
| Posterior | 2.2 ± 1 | 2.7 ± 1.8 | 1.1 ± 0.9 | 1.2 ± 0.5 | 2 ± 0.3 | 2.2 ± 0.2 | 2.2 ± 0.3 | 2.5 ± 1.4 | 1.05 ± 0.2 | 1.15 ± 0.4 | 1.06 ± 0.3 | 0.71 ± 0.1 | 0.70 ± 0.1 | 0.75 ± 0.1 | 0.69 ± 0.2 | |
| Pallidum | External | 4.4 ± 2.7 | 6 ± 4.2 | 2.5 ± 1.6 | 2.3 ± 0.6 | 2.8 ± 0.3 | 3 ± 0.3 | 3.1 ± 0.7 | 3 ± 0.8 | 1.18 ± 0.2 | 1.38 ± 0.3† | 1.26 ± 0.3 | ||||
| Internal | 2.1 ± 2 | 3.1 ± 2.3 | 1.6 ± 1.2 | 2.2 ± 0.8 | 1.4 ± 0.2 | 1.5 ± 0.2 | 1.5 ± 0.4 | 1.7 ± 1 | 1.16 ± 0.2 | 1.37 ± 0.3† | 1.21 ± 0.3 | |||||
| Thalamus | 1.55 ± 0.2 | 1.8 ± 0.4†0.087 | 1.67 ± 0.2 | |||||||||||||
| ACC | Ventral | 0.81 ± 0.3 | 0.9 ± 0.4 | 0.91 ± 0.3 | 1.36 ± 0.4 | 1.64 ± 0.6 | 1.44 ± 0.3 | 1.39 ± 0.3 | ||||||||
| Dorsal | 0.58 ± 0.2 | 0.7 ± 0.2 | 0.67 ± 0.1 | 1.84 ± 0.5 | 2.21 ± 0.6 | 1.99 ± 0.4 | 1.88 ± 0.3 | |||||||||
| Frontal cortex | Dorsolateral | 0.38 ± 0.2 | 0.44 ± 0.3 | 0.41 ± 0.1 | 1.23 ± 0.4 | 1.49 ± 0.4 | 1.37 ± 0.4 | 1.21 ± 0.4 | ||||||||
| Medial | 0.41 ± 0.2 | 0.49 ± 0.3 | 0.45 ± 0.2 | 1.51 ± 0.4 | 1.78 ± 0.5 | 1.63 ± 0.4 | 1.50 ± 0.5 | |||||||||
| Orbital | 0.51 ± 0.3 | 0.62 ± 0.3 | 0.54 ± 0.2 | 1.13 ± 0.3 | 1.34 ± 0.3*0.053 | 1.27 ± 0.2 | 1.10 ± 0.3*‡†‡0.066 | |||||||||
| Ventral | 0.37 ± 0.2 | 0.45 ± 0.3 | 0.39 ± 0.1 | 1.06 ± 0.3 | 1.18 ± 0.3 | 1.18 ± 0.2 | 1.00 ± 0.3 | |||||||||
| Limbic structures | Amygdala | 0.96 ± 0.3 | 0.9 ± 0.3 | 0.91 ± 0.3 | 1.19 ± 0.2 | 1.24 ± 0.2 | 1.26 ± 0.1 | 1.10 ± 0.2 | ||||||||
| Hippocampus | 0.61 ± 0.2 | 0.63 ± 0.2 | 0.6 ± 0.2 | 1.44 ± 0.3 | 1.46 ± 0.2 | 1.44 ± 0.3 | 1.34 ± 0.3 | |||||||||
| Insula | 1.05 ± 0.2 | 1.17 ± 0.3 | 1.09 ± 0.2 | 1.52 ± 0.4 | 1.67 ± 0.4 | 1.62 ± 0.3 | 1.46 ± 0.3 | |||||||||
| Raphe | 1.8 ± 0.2 | 2.17 ± 0.4 | 2.18 ± 0.2 | 0.56 ± 0.2 | 0.58 ± 0.1 | 0.52 ± 0.1 | 0.47 ± 0.3 | |||||||||
Data represent mean Ki or BPND values ± SD. Symbols in italics indicate significant differences. p < 0.05 between states: *baseline versus early symptomatic; †baseline versus full symptomatic; ‡baseline versus; *†early versus full symptomatic; *‡early symptomatic versus recovered; and †‡full symptomatic versus recovered.